Sometimes, one clicks something inadvertently, and lands in the oddest of places. Without any volition on my part, I ended up on the Pharmaceutical Business Review, a wondrous place with innumerable nooks and crannies. Here are just a few samples [some new nose candy and a little something for the itinerant clinical investigators]: FDA grants […]
Kids, Antidepressants & Suicide: Could The Stats Cancel Each Other Out? is a thoughtful blog post by a person who was apparently really helped by anti-depressant medication as an adolescent. Reading Dr. Gibbons’ article [Suicidal Thoughts and Behavior With Antidepressant Treatment], she asks, "Could The Stats Cancel Each Other Out?" After reading it, I think […]
Editorial Coment I’m showing these studies to look at the antidepressant-suicidality-in-adolescents question, but before getting to that, there’s something else. I was taught to be vigilant for graphmanship [using tricks to make graphs look better], so I usually replot data full-scale as I’ve done here. My comment is "no great shakes" in any of these […]
Antidepressant Treatment During Pregnancy Commentary by Margaret Spinelli, M.D. American Journal of Psychiatry. 2012 169:121-124. [full text on-line] A behavioral health outpatient program recently decided that psychiatrists would no longer be permitted to provide new prescriptions for antidepressants to pregnant women because the sponsoring institution had determined that the risk was too high. As a […]
You might be tired of hearing about Martin Keller’s Study 329, but I’m not. So I was glad to see Ed Silverman’s post on Pharmalot yesterday with the primary documents for the latest round between Brown University and the people at Healthy Skepticism. How’s this for a non-response? [click for original] He also had a […]
Dr. Healy’s Pharmageddon is one of those books to be read, not summarized. It’s not that it’s filled with new information. He sees what the rest of us see, albeit from the position more interior than most – a neuroscientist who has been embedded in the scene. He writes about the primacy of the pharmaceutical […]
I wrote a post on the Era of Patent Medicines at the end of the 19th and beginning of the 20th century around this time last year [patent medicine and ambiguity…]. And while this is not my definitive comment on David Healy’s Pharmageddon, it’s his book that got me going on the topic [again]. I […]
Ten-Year Trends in Quality of Care and Spending for Depression 1996 Through 2005 by Catherine A. Fullerton, MD, MPH; Alisa B. Busch, MD, MS; Sharon-Lise T. Normand, PhD; Thomas G. McGuire, PhD; and Arnold M. Epstein, MD Archives of General Psychiatry. 2011 68:1218-1226. Context: During the past decade, the introduction of generic versions of newer […]
Study 329 has been analyzed [Healthy Skepticism], the subject of a book [Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial], been discussed in a number of courtrooms, and is a topic on every blog that has ever focused on the corruption of modern psychopharmacology including this one: Efficacy of Paroxetine in […]
U. will not support Keller retraction by Sahil Luthra February 3, 2012 The University will not support an effort to retract a controversial study co-authored by Professor of Psychiatry and Human Behavior Martin Keller, wrote Edward Wing, dean of medicine and biological sciences, in a recent letter to the global nonprofit Healthy Skepticism. The […]